Clinical trial
Trial of Dasatinib in Advanced Sarcomas
NCT00464620 · Sarcoma Alliance for Research through Collaboration, Other · Completed
Key facts
| NCT number | NCT00464620 |
|---|---|
| Title | Trial of Dasatinib in Advanced Sarcomas |
| Official title | A Phase II Trial of Dasatinib in Advanced Sarcomas |
| Lead sponsor | Sarcoma Alliance for Research through Collaboration, Other |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Rhabdomyosarcoma, Malignant Peripheral Nerve Sheath Tumors, Chondrosarcoma, Sarcoma, Ewing's, Alveolar Soft Part, Chordoma, Epithelioid Sarcoma, Giant Cell Tumor of Bone, Hemangiopericytoma and 1 more |
| Intervention type | Drug |
| Interventions | Dasatinib |
| Enrollment | 366 |
| Start date | May 1, 2007 |
| Primary completion | Dec 1, 2016 |
| Completion | May 1, 2017 |
| First posted | Apr 23, 2007 |
| Last update posted | Nov 23, 2018 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: